{"version":"1.0","type":"link","title":"Response to trastuzumab-deruxtecan in metastatic triple-negative breast cancer with both HER2 mutation and low expression.","author_name":"Amarger CD 외","author_url":"https://prs-insight.online/author/Amarger%20CD","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/89865","thumbnail_width":1200,"thumbnail_height":630}